Productivity Ideas:

Productivity Ideas:

Weekly News Digest: Top 10 Pharma Companies

A digest of 5 stories on each company from Linkboard

UnknownNEWS On Gilead Sciences

The Motley Fool , 1 day ago 
A California District Court jury has found Gilead Sciences (NASDAQ:GILD) guilty of infringing upon patents co-owned by Merck & Co. (NYSE:MRK) and Ionis Pharmaceuticals (NASDAQ:IONS). The jury awarded Merck and Ionis Pharmaceuticals $200 million for …
Watch List News , 10 hours ago 
Fiduciary Trust Co. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 155,767 …
financial-market-news.com , 11 hours ago 
IFC Holdings Incorporated FL increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 65,219 shares of the biopharmaceutical company …
Seeking Alpha , 1 day ago 
Gilead Sciences (NASDAQ:GILD) develops and markets innovative medicines for the treatment of several life-threatening diseases such as Hepatitis C and AIDS. The company’s turnover and profits have skyrocketed during the last few years, as a result of the …
bidnessetc.com , 1 day ago 
Investors should brace for possible gain in Gilead Sciences, Inc. (NASDAQ:GILD) stock as the annual International Liver Conference of the European Association for the Study of the Liver (EASL) draws near. Due to be held this year in Barcelona from April 13 …

News On Johnson And Johnson

Seeking Alpha , 5 days ago 
Johnson & Johnson is a Dividend Champion with 53 consecutive years of dividend growth. Yes, shares are overvalued but investors shouldn’t worry yet. I examine the historic growth of Johnson & Johnson and value the company through a discounted cash flow …
Yahoo Finance , 5 days ago 
Johnson & Johnson’s 1Q16 Results Are Coming Soon: What to Expect (Continued from Prior Part) Pharmaceuticals segment Johnson & Johnson’s (JNJ) Pharmaceutical segment consists of the company’s immunology and infectious disease franchises as well as its …
The Business Insider , 2 days ago 
More than 1,000 people are suing Johnson & Johnson Co. and Imerys Talc America, claiming the producers of baby powder failed to warn them of the product’s connection to ovarian cancer, reports Bloomberg Businessweek. The lawsuits draw from 20 studies …
The Motley Fool , 1 day ago 
On the negative side, Johnson and Johnson’s revenue dropped across the board from 2014 to 2015. All three of the company’s business segments reported year-over-year sales declines, much of which was tied to currency fluctuations outside of the company’s …
CTV News , 2 weeks ago 
Johnson & Johnson has ramped up its ambitious project to learn how to predict who will develop particular diseases and find therapies to prevent or stop the disease early, when it’s most treatable. Since the health care giant announced its groundbreaking …
NEWS On Pfizer
Watch List News , 10 hours ago 
First Midwest Bank Trust Division decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 101,894 shares of the biopharmaceutical company’s stock after selling …
Investopedia , 20 minutes ago 
In November 2015, Allergan and Pfizer Inc. (NYSE: PFE) came together in a reverse buyout, in which Pfizer would be acquired by Allergan to form the largest pharmaceutical company in the world. As of March 17, 2016, the merger, which is valued at over $160 …
FiercePharma , 1 day ago 
Some April Fools’ Day pranks are fun; others, not so much. Pfizer ($PFE) is unamused by an elaborate prank in which a fake press release was sent to and reported on by the Washington Post. The release, and the story, said the pharma giant was holding the …
Yahoo Finance , 1 day ago 
Will Pfizer Report Growth in Its 1Q16 Earnings? (Continued from Prior Part) Growth contributors As discussed earlier, Pfizer’s (PFE) 1Q16 growth is expected to stem from its Innovative Pharmaceuticals business and its alliance revenues. A few key …
NEWS On Roche
Bloomberg , 2 days ago 
Roche Holding AG said it’s open to discussing ways to set prices for tumor-fighting treatments in the U.K., signaling that the world’s biggest maker of cancer drugs will seek to avoid a repeat of last year’s heated dispute with authorities over the …
prnewswire.com , 3 days ago 
“The cobas® Zika test has been specifically designed utilising the generic cobas omni Utility Channel on the cobas® 6800/8800 Systems. These fully-automated high-volume systems provide solutions for blood services to detect the virus and ensure that …
Yahoo Finance , 1 day ago 
The Story behind Roche Holding’s Valuation—and What’s Driving It (Continued from Prior Part) Roche’s diagnostic unit In 2015, Roche Holding’s (RHHBY) diagnostics sales grew by 6%, reaching 10.8 billion swiss francs, or about $10.9 billion. Major …
bidnessetc.com , 2 days ago
The FDA approval for the first ever blood screening Zika test is good news for Puerto Rico, where local blood collections can resume soon Roche Holding Ltd. ADR (OTCMKTS:RHHBY) has won the final approval from the Food and Drug Administration(FDA) to …
financial-market-news.com , 1 day ago 
Roche Holding Ltd. (OTCMKTS:RHHBY)‘s stock had its “buy” rating reaffirmed by equities research analysts at Citigroup Inc. in a report issued on Friday, Analyst Ratings Network.com reports. Other institutional investors recently made changes to their …
NEWS On Novartis
The Business Insider , 11 hours ago 
Thomson ReutersLogo of Swiss drugmaker Novartis is seen at its headquarters in Basel By John Miller ZURICH (Reuters) – Novartis took its campaign to invigorate sluggish sales of its new heart-failure medicine Entresto to a U.S. cardiologists meeting on …
bilbaoya.com , 3 hours ago 
Manning & Napier Advisors raised its position in Novartis AG by 26.2% in the fourth quarter. Manning & Napier Advisors now owns 3,507,436 shares of the company’s stock valued at $301,778,000 after buying an additional 727,330 shares during the last quarter.
Mideast Times , 14 hours ago 
Federated Investors Inc. PA reduced its stake in shares of Novartis AG (NYSE:NVS) by 3.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 45,755 shares of the company’s …
Abruzzo Tv News , 15 hours ago 
Turkish prosecutors have launched an investigation into alleged corruption by Swiss pharmaceutical giant Novartis, the Anatolia news agency said Friday. In February, South Korean law enforcement reportedly seized documents and account books from Novartis …
Watch List News , 1 day ago 
Amica Pension Fund Board of Trustees held its position in Novartis AG (NYSE:NVS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,605 shares of the company’s stock at …
NEWS On Amgen
Watch List News , 11 hours ago 
PNC Financial Services Group Inc. boosted its position in Amgen, Inc. (NASDAQ:AMGN) by 0.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,438,620 shares of the medical …
financial-market-news.com , 12 hours ago 
Buckingham Asset Management LLC reduced its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 2.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 7,002 shares of the medical research company’s stock after selling 181 …
YAHOO!TECH , 18 hours ago 
Many biotech stocks have taken a beating since last August, and it hasn’t just been smaller players feeling the pain. Shares of two of the biggest biotechs — Amgen (NASDAQ:AMGN) and Celgene (NASDAQ:CELG) — are down 15% and 23%, respectively. There’s a …
Mideast Times , 2 days ago 
Amgen, Inc. (NASDAQ:AMGN)‘s stock had its “overweight” rating reissued by Morgan Stanley in a research note issued on Tuesday, Analyst Ratings Network.com reports. They presently have a $193.00 target price on the medical research company’s stock.
Yahoo Finance , 5 days ago 
Will Amgen’s Blockbuster Drugs and Clinical Trials Drive Growth? (Continued from Prior Part) Oncology research programs Expanded indications and increasing market penetration are expected to drive the growth of Amgen’s oncology portfolio in 2016.
Mideast Times , 22 hours ago 
Pictet North America Advisors SA increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 17.8% during the fourth quarter, Holdings Channel reports. The fund owned 31,935 shares of the company’s stock after buying an additional 4,814 shares …
NASDAQ , 5 days ago 
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (Symbol: MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the …
prnewswire.com , 4 days ago 
TO: All persons and entities who, from May 21, 1999, through October 29, 2004, inclusive (the “Settlement Class Period”), purchased or otherwise acquired the common stock of Merck & Co., Inc. (“Merck Common Stock”) or call options on Merck Common Stock …
Watch List News , 4 days ago 
Merck & Co., Inc. (NYSE:MRK) traded up 0.85% during midday trading on Tuesday, reaching $53.28. 4,623,901 shares of the company’s stock were exchanged. The stock has a market cap of $147.87 billion and a P/E ratio of 34.15. The firm’s 50-day moving …
The Motley Fool , 1 week ago 
A jury in Northern California has weighed in and decided that Gilead Sciences’ (NASDAQ:GILD) mega-blockbuster drugs Sovaldi and Harvoni violate two patents co-owned by Merck & Co (NYSE:MRK) and Ionis Pharmaceuticals (NASDAQ:IONS). However, the $200 million …
NEWS On Sanofi
financial-market-news.com , 1 day ago 
South Dakota Investment Council continued to hold its stake in shares of Sanofi SA (NYSE:SNY) during the fourth quarter, according to its most recent filing with the SEC. The firm owned 27,327 shares of the company’s stock at the end of the fourth quarter.
Fierce Biotech , 10 hours ago 
Regeneron ($REGN) and Sanofi ($SNY) have rung up stellar late-stage data from a pair of large Phase III studies of the blockbuster antibody contender dupilumab, putting it on a straight path to the FDA. Tapped by a number of analysts as one of the biggest …
This Day Live , 2 days ago 
The launch of Zentiva in Nigeria, the third largest and fastest growing generics company in Europe, by Sanofi, is seen as a move to ameliorate the plight of many, for whom affordable healthcare was out of reach. Writes Mary Ekah Records abound of …
Watch List News , 1 day ago 
Amica Mutual Insurance Co. continued to hold its position in Sanofi SA (NYSE:SNY) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,892 shares of the company’s …
Wall Street Journal , 2 days ago 
Regeneron Pharmaceuticals Inc. and Sanofi SA said their experimental drug for a debilitating skin condition called atopic dermatitis met all of its major treatment targets in two late-stage studies, a key step in advancing a potential blockbuster medicine …
NEWS On AbbVie
Ticker Report , 1 hour ago 
Traders sold shares of AbbVie Inc (NASDAQ:ABBV) on strength during trading on Friday, Market Beat Ratings reports. $41.56 million flowed into the stock on the tick-up and $88.98 million flowed out of the stock on the tick-down, for a money net flow of $47 …
The Motley Fool , 1 day ago 
Investors have made a lot of money from Big Pharma stocks over the past few years. Two of the biggest winners have quite different backgrounds. AbbVie (NYSE:ABBV) is a spin-off less than four years old. Johnson & Johnson (NYSE:JNJ) has been around since …
Mideast Times , 10 hours ago 
Hendershot Investments Inc. raised its position in AbbVie Inc (NASDAQ:ABBV) by 13.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 138,288 shares of the company’s stock after buying an additional …
Watch List News , 11 hours ago 
AbbVie Inc (NASDAQ:ABBV) has earned an “A-” credit rating from analysts at Morningstar. The research firm’s “A-” rating indicates that the company is a low default risk. They also gave their stock a four star rating. Shares of AbbVie (NASDAQ:ABBV …
Seeking Alpha , 5 days ago 
AbbVie is the maker of the top-selling drug in the world, Humira. Although the composition patent for Humira expires this year, there are still dozens more. The stock remains undervalued following the big selloff in October of last year. AbbVie (NYSE:ABBV …
News On AstraZeneca
FIRSTPOST , 4 HOURS 
They experienced a 40 percent reduced risk of heart attack and stroke over a six-year period when taking AstraZeneca Plc’s Crestor statin as well as a combination tablet containing blood pressure treatment candesartan and the diuretic hydrochlorothiazide.
THE HERALD OF EVERETT , 7 HOURS AGO
The editorial authors said other statins would likely have similar results. Crestor’s maker, AstraZeneca, and the Canadian Institutes of Health Research paid for the study. Yusuf reported receiving grants from both; and several co-researchers reported …
FORBES , 5 HOURS AGO
Hope-3 was funded by the Canadian Institutes of Research and Health and AstraZeneca, which makes some of the drugs used in the study. Hope-3 was designed to test a big idea: The PolyPill. With a PolyPill, a combination of low-dose blood pressure drugs …
DAILY NEWS AND ANALYSIS , 4 HOURS AGO
They experienced a 40 percent reduced risk of heart attack and stroke over a six-year period when taking AstraZeneca Plc’s Crestor statin as well as a combination tablet containing blood pressure treatment candesartan and the diuretic hydrochlorothiazide.
THE NEW ENGLAND JOURNAL OF MEDICINE , 6 HOURS AGO
(Funded by the Canadian Institutes of Health Research and AstraZeneca; ClinicalTrials.gov number, NCT00468923.) The trial was designed by an international steering committee of academic investigators and sponsored by AstraZeneca and the Canadian Institutes …

Leave a Reply